论文部分内容阅读
希美纳是目前在临床唯一正式应用的放射增敏剂,国家一类新药; 希美纳能浓集于肿瘤组织,选择性地杀伤肿瘤组织中对射线有抗拒作用的乏氧细胞,从而提高肿瘤放疗的效果; 希美纳适用于进行放疗的鼻咽癌、食管癌、肺癌、宫颈癌等实体瘤患者; 有文献报道,放疗加注射用甘氨双唑钠(希美纳)治疗宫颈鳞癌患者的CR率(完全缓解率)为90%,而单纯放疗患者的CR率为60%(P<0.05),两组患者不良反应及严重程度的比较无统计学意义。
Ximei Na is currently the only officially applied in the clinical radiosensitizer, a national class of new drugs; Ximei Na concentrated in the tumor tissue, selective killing of tumor cells in radiation-resistant hypoxic cells, thereby enhancing tumor radiotherapy ; Ximei Na for radiotherapy for nasopharyngeal carcinoma, esophageal cancer, lung cancer, cervical cancer and other solid tumors; it has been reported in the literature, radiotherapy plus injection of sodium glycididazole (Ximei Na) treatment of cervical squamous cell carcinoma in patients with CR The CR rate was 90%, while the CR rate in radiotherapy alone was 60% (P <0.05). The adverse reactions and the severity of the two groups were not statistically significant.